TCTR20210917003进行中（未招募）不适用
Immunogenicity and safety of COVID-19 vaccines in SLE and rheumatoid arthritis patients
Ratchadapiseksompotch Fund, Faculty of Medicine0 个研究点目标入组 100 人开始时间: 2021年9月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Age 18-65 years old
- •Diagnosis of SLE according to American College of Rheumatology (ACR) 1997 or The Systemic Lupus International Collaborating Clinics (SLICC) criteria or or EULAR/ACR classification
- •Diagnosis of RA according to 2010 ACR and European League Against Rheumatism (EULAR) classification criteria for rheumatoid arthritis
排除标准
- •History of SARS-CoV-2 infection
- •Receipt of covid-19 vaccine prior to study enrollment
- •Severe extra-renal involvement of SLE
- •Receipt of prednisolone > 20 mg/day
- •Receipt of mycophenolate mofetil(MMF) > 1.5 g/day
- •Receipt of azathioprine > 2 mg/kg/day
- •Treatment with cyclophosphamide within 1 month
- •Treatment with biologic agents within the past 6 months
- •Severe SLE flare including: CNS involvement, Vasculitis, Nephritis, Platelet < 60,000, Hemolytic anemia: Hgb < 7 g/dL or decrease in Hgb > 3 g/dL
- •Not receiving immunosuppressive treatment
研究者
相似试验
已完成
不适用
Safety and immunogenicity of COVID-19 vaccines for SARS-CoV-2 in lung cancer patientsCOVID vaccine in lung cancerCOVID-19 VaccinesCarcinoma, Non-Small-Cell LungSmall Cell Lung CarcinomaLung NeoplasmsTCTR20240811003Faculty of Medicine, Chiang Mai University73
已完成
4 期
The immune-response and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplantNL-OMON51071niversitair Medisch Centrum Groningen850
进行中（未招募）
1 期
The efficacy and safety of COVID-19 vaccination in patients with a kidney diseaseCOVID-19 is associated with increased morbidity and mortality in kidney transplant recipients (KTR) and patients with chronic kidneydisease (CKD). Therefore, potential efficacious SARS-CoV-2 vaccination would be of great clinical importance in these patients.However, SARS-CoV-2 vaccination studies have excluded KTR and patients with CKD so-far. This will be the subject of this trial.MedDRA version: 20.0Level: LLTClassification code 10023438Term: Kidney transplantSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 20.0Level: PTClassification code 10061105Term: DialysisSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.1Level: PTClassification code 10064848Term: Chronic kidney diseaseSystem Organ Class: 10038359 - Renal and urinary disordersMedDRA version: 23.1Level: LLTClassification code 10084465Term: COVID-19 vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.1Level: LLTClassification code 10084401Term: COVID-19 respiratory infectionSystem Organ Class: 100000004862MedDRA version: 23.1Level: LLTClassification code 10084464Term: COVID-19 immunizationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084272Term: SARS-CoV-2 infectionSystem Organ Class: 100000004862MedDRA version: 23.0Level: LLTClassification code 10084462Term: SARS-CoV-2 vaccinationSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 23.0Level: LLTClassification code 10084463Term: SARS-CoV-2 immunisationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2021-000868-30-NLRECOVAC consortium850
尚未招募
不适用
Immunogenicity and safety COVID-19 vaccine in healthy adults: a single institute based cohort studyCOVID-19JPRN-UMIN000043589Saga University60
招募中
4 期
The safety and efficacy of COVID-19 vaccines among lung transplant recipientslung transplant recipientslung transplant, solid organ transplant, COVID-19JPRN-jRCT1021210009Okada Yoshinori80